Bausch + Lomb Advances Two Eye Therapies With Blockbuster Sales Potential
Bausch + Lomb (NYSE: BLCO) advances two first-in-class eye drugs to advanced clinical testing, eyeing $2B+ in peak sales.
Read original at benzingaStocks · News reference
Bausch + Lomb Announces U.S. Launch Of EyeGility Inserter Preloaded IOL Delivery System
EyeGility is designed for the enVista® family of IOLsOffers balanced push force for smooth delivery, convenient one-handed operationAvailable now for enVista Aspire™; will be available for enVista Envy™ in the coming
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 16, 2026, 11:05 AM
- Checked
- Jul 16, 2026, 11:05 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Bausch + Lomb Says Dual-Action Dry Eye Drop Missed Phase 2 Primary Endpoint At Day 29, Met Secondary Endpoint At Day 15; Advancing To Phase 3 With Day 15 Primary Endpoint
Read original at benzingaCarl Icahn Trims JetBlue, AEP Stakes While Sitting Out New Stock Bets
Carl Icahn made no new stock purchases in Q2, trimming stakes in JetBlue and American Electric Power. The rest of his portfolio is unchanged.
Read original at benzinga8-K/A filing — Bausch & Lomb Corp (BLCO)
Filed: 2026-08-12 AccNo: 0000950103-26-012223 Size: 191 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read original at edgarBausch & Lomb Q2 Adj. EPS $0.16, Inline, Sales $1.394B Beat $1.368B Estimate
Read original at benzingaBausch + Lomb Announces Phase 2 Topline Results For BL1107 In Glaucoma; Study Did Not Meet Primary Endpoint Of Replicating Earlier Visual Gains, And Company Will Discontinue Development As Topical Eye Drop
Read original at benzinga